May 6 | 2022

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

Read more
May 6 | 2022

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

Read more
May 5 | 2022

Redeye research interview with 2cureX CEO, Fernando Andreu

Read more
April 14 | 2022

Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program

Read more
March 15 | 2022

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Read more
March 14 | 2022

2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022

Read more
February 23 | 2022

2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.

Read more
January 21 | 2022

New Institutional shareholder

Read more
January 11 | 2022

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

Read more
January 5 | 2022

IndiTreat® to be distributed in Poland by Perlan Technologies

Read more
December 16 | 2021

First hospital joins the IndiTreat® Evaluation Program IGNITE

Read more
December 14 | 2021

2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment

Read more
December 13 | 2021

2cureX reaches the goals for the 2021 rollout plan

Read more
December 9 | 2021

2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey

Read more
November 29 | 2021

EU publishes an article about the successful finalization of 2cureX’s MicroCaT project.

Read more
November 24 | 2021

2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK

Read more
October 29 | 2021

Mangold Fondkommission AB published an updated Analyst Report on 2cureX

Read more
October 15 | 2021

2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant.

Read more